Ray Sumita 4

What Happened

• Ray Sumita, Chief Legal Compliance Officer and Corporate Secretary of Cue Biopharma (CUE), received equity awards on 2026-07-09: 54,589 restricted stock units (RSUs) and 54,589 performance stock units (PSUs). Both awards were recorded at $0.00 per share (typical for compensation grants). Total units granted = 109,178.

Key Details

• Transaction date: 2026-07-09; Form 4 filed 2026-07-10 (timely).
• Grant type(s): A = Award/Grant. One grant reported as RSUs (non-derivative); the other reported as PSUs (derivative/security-based on performance).
• Price: $0.00 per unit; aggregate cash value shown as $0 on the filing.
• Vesting:
  • RSUs: vest in equal quarterly installments over 48 months from grant date, subject to continued service. (Footnote F1)
  • PSUs: three substantially equal tranches tied to stock-price targets ($33.00, $38.50, $44.00) that require a closing price for five consecutive trading days; if targets aren’t met within 24 months, the PSUs are forfeited. (Footnote F2)
• Shares owned after the transaction: not specified in this filing.
• Filing timeliness: filed within the required Form 4 window (not marked late).

Context

• These awards are compensation grants (not open-market purchases or sales) and are common for executives; they do not represent an immediate cash investment or sale. PSUs are contingent/derivative awards that only convert to shares if performance targets are met; RSUs vest over time with continued service.